Handbook of clinical drug data - part 9 pps

... smokingand type of delivery. Soc Sci Med 199 1;33:1 391 –7.176. Hopkinson JM et al. Milk production by mothers of premature infants: influence of cigarette smoking. Pedi-atrics 199 2 ;90 :93 4–8.177. ... JAMA 199 5;273: 795 –8.1 79. Håkansson A, Cars H. Maternal cigarette smoking, breast-feeding, and respiratory tract infections. Amatched-pair study. Scand J Prim Health Care 199 1 ;9: 115 9. 94 2 DRUGUSE ... of drug therapy, and, conversely, drug therapy can affect nutritional sta-tus. 19, 36,37■ EVALUATING DRUG DATA FOR THE ELDERLYBecause of age-related changes that may impact the outcome of drug...

Handbook of clinical drug data - part 2 pps

... nearly all isolates of Staphylococcus aureus and some isolates of coagulase-negative staphylococci aresusceptible to these drugs. Methicillin- (actually ␤-lactam-) resistant staphylo-cocci have altered ... include those of amoxi-cillin; however, diarrhea is more frequent with the combination and depends onthe dosage of clavulanate. The 12-hr formulations reduce the frequency of diar-rhea. Nausea ... (startwithin 48 hr of onset of symptoms) 10 mg (2 inhalations) bid for 5 days. Givethe first dose under the supervision of an informed healthcare professional to ob-serve correct use of the inhalation...

Handbook of clinical drug data - part 3 ppsx

... Drug Interactions. (Aminoglutethimide) Several drug interactions can occur be-cause of the drug s enhancement of CYP3A metabolism; the effects of dexam-ethasone, digoxin, ... interrupted at a number of enzymatic sites, including the conver-sion of inosinic acid to adenine- or xanthine-based ribosides. DNA and RNA syn-thesis is halted in a cell-cycle S-phase–specific fashion.Administration ... Alfa-2a and 2b are 100% bioavailableafter IM or SC administration, with an absorption half-life of about 6 hr. IM or SCINTERFERON ALFA:ALFA-2A Pegasys, Roferon-AALFA-2B Intron A, PEG-IntronALFA-N3...

Handbook of clinical drug data - part 4 pptx

... bioavailable be-cause of extensive first-pass elimination; bioavailability increases in liverdisease.251Covera-HS provides a 4- to 5-hr delay before releasing the drug. Ver-apamil has stereospecific ... risk of bone fracture by increasingbone density, the risk of DVT and the risk of becoming diabetic.258, 29 0-2 92 Administration and Adult Dosage. Adjust dosage at no less than 4-week inter-vals. ... of any other drug. Pharmacology. Omapatrilat is the first of a new class of drugs called vasopepti-dase inhibitors. Omapatrilat inhibits ACE and neutral endopeptidase, leading toblockades of...

Handbook of clinical drug data - part 5 ppt

... hr. 292 Levodopa Vdis1. 09 ± 0. 59 L/kg; Cl is 0.28 ± 0.06 L/hr/kg; 90 % of clearance is nonrenal. 293 t¹⁄₂. (Carbidopa) 2.1 ± 0.6 hr; 292 (levodopa alone) 1.4 ± 0.3 hr; (levodopa with car-bidopa) ... the first of a class of selective serotonin-5-HT1Are-ceptor partial agonists. It also has some effect on dopamine-D2autoreceptors and,like antidepressants, can downregulate ␤-adrenergic ... is 97 %bound to plasma proteins and has a Vd of 1–3 L/kg; Cl is 0.25–0.54 L/hr/kg.Midazolam is hepatically metabolized via CYP3A4 to the 1-hydroxy- and 4-hydroxy-metabolites; the 1-hydroxy-metabolite...

Handbook of clinical drug data - part 6 pdf

... of therapeutics. 9th ed. New York: McGraw-Hill; 199 6:1707 92 .80. Wall ME et al. Metabolism, disposition, and kinetics of delta -9 - tetrahydrocannabinol in men and women. ClinPharmacol Ther 198 3;34:352–63.81. ... Selectivity of 5-HT3receptor antagonists and anti-emetic mechanisms of action. AnticancerDrugs 199 2;3: 79 85.88. Holdsworth MT et al. Assessment of chemotherapy-induced emesis and evaluation of a ... survey of oncologists’ experiences and atti-tudes. J Clin Oncol 199 1 ;9: 1314 9. 86. Adams VR, Valley AW. Granisetron: the second serotonin-receptor antagonist. Ann Pharmacother 199 5; 29: 1240–51.87....

Handbook of clinical drug data - part 7 ppt

... Endocrinol Metab 199 4;78: 197 –204.1 39. Steinberg KK et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.JAMA 199 1;265: 198 5 90 . {Erratum JAMA 199 1:266:1362.}140. ... Mosby-Year Book; 199 4:225–54.42. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 199 9;57: 19 29. 43. Lebovitz HE. ␣-Glucosidase inhibitors in the treatment of hyperglycemia. ... withraloxifene. JAMA 199 9;282:637–45.155. Cummings SR et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 199 9;281;21 89 97 .156. Walsh BW et al. Effects of raloxifene...

Handbook of clinical drug data - part 8 pptx

... Association; 199 3: 89 115.75. American Academy of Pediatrics. Committee on Drugs. Use of codeine- and dextromethorphan-containingcough syrups in pediatrics. Pediatrics 199 7 ;99 :91 8–20.76. Shaul ... 197 7; 59: 117 9. 77. Katona B, Wason S. Dextromethorphan danger. N Engl J Med 198 6;314 :99 3. Letter.78. Bem JL, Peck R. Dextromethorphan. An overview of safety issues. Drug Safety 199 2; 190 9. 79. ... Editorial. 98 . Love BB et al. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf 199 8; 19: 89 98 . 99 . Steinhubl SR et al. Incidence and clinical course of thrombotic...

Handbook of clinical drug data - part 10 doc

... hepatic encephalopa-thy. Ann Surg 198 2; 196 :2 09 20.27. Freund H et al. Infusion of the branched-chain amino acids in postoperative patients: anticatabolic properties.Ann Surg 197 9; 190 :18–23.NUTRITIONSUPPORT10 49 ch16.qxd ... alsoClomipramineANALGESIC AND ANTI-INFLAMMATORYDRUGS, 3–54antimigraine drugs, 3 9 antirheumatic drugs, 10–15breastfeeding, 91 6 91 8nephrotoxicity, 843nonsteroidal anti-inflammatorydrugs, 16–30opioids, ... assessment,10 29 1030ANTIALLERGICS, pregnancy, 897 ANTI-ANDROGENS, 245–246ANTIARRHYTHMIC DRUGS, 297 –321,322–323breastfeeding, 92 2 92 3pregnancy, 887ANTIASTHMATICS, 7 69 776,777–781, 782–785, 786–7 89, 790 breastfeeding,...

Xem thêm